Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 601–700 of 2,932
Antifungal properties of cathelicidin LL-37: current knowledge and future research directions
Memariani, M., & Memariani, H. (2023) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-023-03852-5 · Cited by 27
“Even though the epidemiology of fungal diseases has undergone many changes over the past decades, certain pathogens such as Aspergillus , Candida , Cryptococcus , Pneumocystis , and Histoplasma are still the principal culprits implicated in the invasive forms of mycoses (Bongomin et al. 2017).”
InfluentialUnderstanding the riboflavin biosynthesis pathway for the development of antimicrobial agents
Kundu, B., Sarkar, D., Ray, N., & Talukdar, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21576 · Cited by 28
Gładkowski, W., Siepka, M., Janeczko, T., et al. (2019) · Molecules · doi:10.3390/molecules24224151 · Cited by 25
“Early diagnosis allows the application of proper therapy; incorrect treatment may cause complications, including serious chronic illness or even death [2].”
BackgroundUnveiling the menace: a thorough review of potential pandemic fungal disease
Jafarlou, M. (2024) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2024.1338726 · Cited by 24
The Microevolution of Antifungal Drug Resistance in Pathogenic Fungi
Boyce, K. J. (2023) · Microorganisms · doi:10.3390/microorganisms11112757 · Cited by 29
Ahmed, S., Farag, M. M., Attia, H., Balkhi, B. S., Adel, I. M., & Nemr, A. A. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100333 · Cited by 36
“…its shadow over tropical and sub-tropical regions, where it manifests in up to 60 % of mycotic keratitis instances, likely attributable to humid temperate climate (Bongomin et al., 2017) and the prevalence of agricultural activities predisposing individuals to ocular trauma (Leck et al., 2002).”
Martín-Gómez, M. T., Goterris, L., Martínez‐Martí, A., Sampol, J., Roldán, E., Almirante, B., & Ruíz-Camps, I. (2019) · Mycoses · doi:10.1111/myc.12950 · Cited by 26
Sueiro-Olivares, M., Scott, J., Gago, S., Petrovic, D., Kouroussis, E., Živanović, J., Yu, Y., Strobel, M., Cunha, C., Thomson, D. D., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001247 · Cited by 23
“The latest estimates calculate a global incidence for IA higher than 300,000 (suspected to be an underestimate) and a mortality rate ranging from 30% to 80% [16].”
BackgroundSelf-citationPfaller, M. A., Carvalhaes, C. G., Rhomberg, P. R., Messer, S. A., & Castanheira, M. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00431-4 · Cited by 29
Archer, M., & Xu, J. (2021) · Genes · doi:10.3390/genes12070960 · Cited by 22
“8 million cases of allergic bronchopulmonary aspergillosis (including asthma), 3 million cases of chronic pulmonary aspergillosis and 250,000 cases of invasive aspergillosis [12].”
BackgroundVerma, R., Pradhan, D., Hasan, Z., Singh, H., Jain, A. K., & Khan, L. A. (2021) · Medical Mycology · doi:10.1093/mmy/myab058 · Cited by 31
Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing
Jong Heon, K. I. M., Cheng, L. W., & Land, K. M. (2022) · Pharmaceuticals · doi:10.3390/ph15070787 · Cited by 30
“Candidiasis is an infectious disease caused by the genus Candida which has been the second-highest cause of superficial/mucosal human infections and the fourth highest cause of bloodstream infections [10,11].”
BackgroundZhang, Q., Zhang, Z., Zou, X., Liu, Z., Li, Q., Zhou, J., Gao, S., Xu, H., Guo, J., & Yan, F. (2023) · Biomaterials Science · doi:10.1039/d2bm02096c · Cited by 25
Safety and usefulness of nebulized liposomal amphotericin B: Systematic scoping review
Hagiya, H., Nishimura, Y., & Otsuka, F. (2023) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2023.102233 · Cited by 27
Vanhoffelen, E., Michiels, L., Brock, M., Lagrou, K., Reséndiz-Sharpe, A., & Velde, G. V. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00825-23 · Cited by 25
Nano-based theranostic approaches for infection control: current status and perspectives
Huang, R., Hu, Q., Ko, C.-N., Tang, F. K., Xuan, S., Wong, H. M., Jin, L., Li, X., & Leung, K. C. (2023) · Materials Chemistry Frontiers · doi:10.1039/d3qm01048a · Cited by 31
Ibrexafungerp: A narrative overview
Ayoubi, L. W. E., Allaw, F., Moussa, E., & Kanj, S. S. (2024) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2024.100245 · Cited by 41
“The global impact of IFI is staggering, affecting over a billion individuals, and contributing to more than 1.5 million deaths annually (Bongomin et al., 2017).”
BackgroundInfluentialAlshehri, S., Hussain, A., Ahsan, M. N., et al. (2021) · ACS Omega · doi:10.1021/acsomega.0c06234 · Cited by 24
Fc‐conjugated C‐type lectin receptors: Tools for understanding host–pathogen interactions
Willment, J. A. (2021) · Molecular Microbiology · doi:10.1111/mmi.14837 · Cited by 25
“Fungi cause significant disease with more than a million deaths and significantly more life-threatening infections per annum with most fungi-opportunistic pathogens causing disease in patients with compromised immune systems (Bongomin et al., 2017).”
BackgroundApproaches for identifying and measuring heteroresistance in azole-susceptible Candida isolates
Gautier, C., Maciel, E. I., & Ene, I. V. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04041-23 · Cited by 23
Salzer, H. J. F., Reimann, M., Oertel, C., Davidsen, J. R., Laursen, C. B., Braeckel, E. V., Agarwal, R., Avsar, K., Munteanu, O., Irfan, M., et al. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.08.032 · Cited by 26
Nucleic-Acid-Based Molecular Fungal Diagnostics: A Way to a Better Future
Gudisa, R., Harchand, R., & Rudramurthy, S. M. (2024) · Diagnostics · doi:10.3390/diagnostics14050520 · Cited by 29
Yang, S., Ji, Y., Xue, P., Li, Z., Chen, X., Shi, J., & Jiang, C. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134306 · Cited by 30
Halliday, C. L., Tay, E. S. E., Green, W., Law, D., Lopez, R., Faris, S., Meehan, L., Harvey, E., Birch, M., & Chen, S. C. ‐. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae267 · Cited by 23
New antifungal strategies and drug development against WHO critical priority fungal pathogens
Li, Y., Liu, Y., Jiang, Y., Yang, Y., Ni, W., Zhang, W., & Tan, L. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1662442 · Cited by 53
Estimated Burden of Fungal Infections in Namibia
Dunaiski, C. M., & Denning, D. W. (2019) · Journal of Fungi · doi:10.3390/jof5030075 · Cited by 27
“Recent global estimates found ~1,300,000 cases from HIV-positive cases only, of which 20% had CD4 counts <200 and 5% of those were on ARVs [62].”
BackgroundSelf-citationInteractions between invasive fungi and symbiotic bacteria
Wang, F., Xin, C., Liu, J., Ran, Z., Zhao, C., & Song, Z. (2020) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-020-02913-3 · Cited by 27
Improved Skin Disease Classification Using Generative Adversarial Network
Mondal, B., Das, N., Santosh, K., & Nasipuri, M. (2020) · Proceedings - IEEE Symposium on Computer-Based Medical Systems · doi:10.1109/cbms49503.2020.00104 · Cited by 25
“Skin diseases, one of the primary concern of public health generally gets neglected by the common people throughout the world [1].”
BackgroundPfister, J., Petřík, M., Bendová, K. D., Matuszczak, B., Binder, U., Kühbacher, A., Gsaller, F., Misslinger, M., Haas, H., & Decristoforo, C. (2021) · Journal of Fungi · doi:10.3390/jof7070558 · Cited by 25
“Invasive aspergillosis (IA) is a severe infection in humans, associated with high mortality and an estimated incidence of 250,000 cases a year worldwide [1,2].”
BackgroundUnderstanding the pathogenesis of infectious diseases by single-cell RNA sequencing
Huang, W., Wang, D., & Yao, Y. (2021) · Microbial Cell · doi:10.15698/mic2021.09.759 · Cited by 27
“5 million deaths worldwide each year [73].”
DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis
Ambati, S., Pham, T., Lewis, Z., Lin, X., & Meagher, R. B. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01467-21 · Cited by 26
“4 Introduction 43 Invasive candidiasis is among top 4 most life-threatening fungal diseases (1-5).”
Akram, W., Ejaz, M. B., Mallhi, T. H., Sulaiman, S. A. B. S., & Khan, A. H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259766 · Cited by 29
Tang, H., Lin, Y., Huang, L., & Hu, J. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.1.41 · Cited by 30
Valero, C., Colabardini, A. C., de Castro, P. A., Amich, J., Bromley, M. J., & Goldman, G. H. (2022) · mBio · doi:10.1128/mbio.00447-22 · Cited by 23
Nargesi, S., Jafarzadeh, J., Najafzadeh, M. J., Nouripour‐Sisakht, S., Haghani, I., Abastabar, M., İlkit, M., & Hedayati, M. T. (2022) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001480 · Cited by 24
Breuer, M. R., Dasgupta, A., Vasselli, J. G., Lin, X., Shaw, B. D., & Sachs, M. S. (2022) · Journal of Fungi · doi:10.3390/jof8060642 · Cited by 21
Targeting DNA Topoisomerase II in Antifungal Chemotherapy
Kondaka, K., & Gabriel, I. (2022) · Molecules · doi:10.3390/molecules27227768 · Cited by 25
“There is a need of appropriate diagnosis as those that go undiagnosed at the initial stage may lead to severe acute diseases and thus open a pathway for other microbial infections and bacterial attacks [2].”
BackgroundPoyraz, S., Döndaş, H. A., Yamalı, C., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2214224 · Cited by 23
“Due to increasing resistance problems, the discovery of new antimicrobial molecules with an effective treatment profile has become more important (Bongomin et al., 2017).”
BackgroundPfaller, M. A., Carvalhaes, C. G., Rhomberg, P. R., Desphande, L. M., & Castanheira, M. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01141-23 · Cited by 24
“Over the past two decades, both the frequency of IA and resistance to azoles have increased throughout the world, with the highest rates of resistance reported from Europe (especially the Netherlands) followed by North America (mostly in the USA) (3, 5–8).”
BackgroundThomsen, J., Abdulrazzaq, N. M., Oulhaj, A., Nyasulu, P. S., Alatoom, A. A., Denning, D. W., Dhaheri, F. A. A., Menezes, G. A., Moubareck, C. A., Senok, A. C., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1244358 · Cited by 30
Self-citationCompetitive fungal commensalism mitigates candidiasis pathology
Kralova, J. S., Donic, C., Dassa, B., Livyatan, I., Jansen, P. M., Ben‐Dor, S., Fidel, L., Trzebanski, S., Narunsky-Haziza, L., Asraf, O., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231686 · Cited by 23
Risk and impact of invasive fungal infections in patients with multiple myeloma
Tsai, C., Liu, Y., Kuan, A. S., Lee, K., Yeh, C., Lee, Y.-T., Hsiao, L., Ko, P., Wang, H., Chen, P., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04125-z · Cited by 22
“reported that Vietnam had one of the highest burdens of invasive aspergillosis and it may be due to its tropical climate [21].”
BackgroundAndrade, J. T., Lima, W. G., Sousa, J. F., Saldanha, A. A., de Sá, N. P., Morais, F. B., Silva, M. K. P., Viana, G. H. R., Johann, S., Soares, A. C., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113048 · Cited by 24
The Added Value of [18F]FDG PET/CT in the Management of Invasive Fungal Infections
Ankrah, A. O., Creemers-Schild, D., de Keizer, B., Klein, H. C., Dierckx, R., Kwee, T. C., Span, L. F. R., de Jong, P. A., Sathekge, M. M., & Glaudemans, A. W. J. M. (2021) · Diagnostics · doi:10.3390/diagnostics11010137 · Cited by 24
“Invasive fungal infections (IFIs) cause significant morbidity and mortality, especially in immunocompromised hosts [1].”
BackgroundMead, M. E., Steenwyk, J. L., Silva, L. P., de Castro, P. A., Saeed, N., Hillmann, F., Goldman, G. H., & Rokas, A. (2021) · Genetics · doi:10.1093/genetics/iyab066 · Cited by 22
Caldeirão, A. C. M., Araujo, H. C., Tomasella, C. M., Sampaio, C., Oliveira, M. J. D. S., Ramage, G., Pessan, J. P., & Monteiro, D. R. (2021) · Antibiotics · doi:10.3390/antibiotics10050588 · Cited by 28
“Nonetheless, Candida glabrata has been recognized as an important candidiasis-related pathogen in recent years, mainly due to its resistance to antifungal treatments [8] and high prevalence in systemic infections [12].”
BackgroundWang, X. (2021) · Infectious diseases · doi:10.5772/intechopen.87410 · Cited by 22
silva, P. H. D. S., Fernandes, C., Barros, L., Ferreira, I. C. F. R., Pereira, L., & Gonçalves, T. (2018) · Food & Function · doi:10.1039/c8fo01797b · Cited by 29
Fusarium Keratitis: A Systematic Review (1969 to 2023)
Cintra, M. E. C., Dantas, M. D. S., Al‐Hatmi, A. M. S., Bastos, R. W., & Rossato, L. L. (2024) · Mycopathologia · doi:10.1007/s11046-024-00874-x · Cited by 24
“Due to the climate (increased temperatures and relative humidity) and frequent ocular injuries related to agriculture, the burden of MK is highest in tropical and subtropical regions, accounting for 20–60% of MK cases [13].”
Candida glabrata: A Tale of Stealth and Endurance
Askari, F., & Kaur, R. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00477 · Cited by 24
Tischler, B. Y., Tosini, N. L., Cramer, R. A., & Hohl, T. M. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008544 · Cited by 26
“IA develops in an estimated 200,000 patients worldwide annually [2] and has high fungus-attributable mortality rates, typically 20–25% in high-risk groups [3], despite receipt of contemporary antifungal drugs.”
Yamazaki, H., Yagi, A., Takahashi, O., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127375 · Cited by 22
Wu, S.-L., Cheng, C., Wang, C., Lin, S., & Kuo, C. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115157 · Cited by 23
Novel Biological Functions of the NsdC Transcription Factor in Aspergillus fumigatus
de Castro, P. A., Valero, C., Chiaratto, J., Colabardini, A. C., Pardeshi, L. A., Silva, L. P., Almeida, F. B. D. R., Rocha, M. C., Silva, R. N., Malavazi, I., et al. (2021) · mBio · doi:10.1128/mbio.03102-20 · Cited by 26
Gaur, V., Patel, K., & Pałka, Ł. (2021) · Journal of Prosthetic Dentistry · doi:10.1016/j.prosdent.2020.12.022 · Cited by 24
Dependence on Mincle and Dectin-2 Varies With Multiple Candida Species During Systemic Infection
Thompson, A., da Fonseca, D. M., Walker, L. A., Griffiths, J. S., Taylor, P. R., Gow, N. A. R., & Orr, S. J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.633229 · Cited by 26
Ning, Y., Yang, W., Zhang, W., Xiao, M., Wang, Y., Zhang, J., Zhang, G., Duan, S., Dong, A., Guo, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.687240 · Cited by 22
Pharmaceutical Multicomponent Crystals of Antifungal Drugs with Improved Dissolution Performance
Drozd, K. V., Manin, A. N., Boycov, D. E., Churakov, A. V., & Perlovich, G. L. (2021) · Crystal Growth & Design · doi:10.1021/acs.cgd.1c01139 · Cited by 22
Chibabhai, V. (2022) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v37i1.326 · Cited by 25
Holzknecht, J., Dubrac, S., Hedtrich, S., Galgóczy, L., & Marx, F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00299-22 · Cited by 23
Jaiswal, N., & Kumar, A. (2022) · Microchemical Journal · doi:10.1016/j.microc.2022.107572 · Cited by 24
Genomic Variation-Mediating Fluconazole Resistance in Yeast
Wang, W., Cai, H., Qu, S.-Y., Lin, W., Liang, C., Liu, H., Xie, Z., & Yuan, Y. (2022) · Biomolecules · doi:10.3390/biom12060845 · Cited by 22
“6 million deaths annually, and more than 10 million people have mucosal candidiasis [1,2].”
BackgroundHan, H. L., Jiang, L., Tran, T. N. T., et al. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.136004 · Cited by 22
Wang, J., Meng, S., Lin, K., Yi, X., Sun, Y., Xu, X., He, N., Zhang, Z., Hu, H., Qie, X., et al. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.340658 · Cited by 25
Development and Application of a Short Tandem Repeat Multiplex Typing Assay for Candida tropicalis
Spruijtenburg, B., van Haren, M. H. I., Chowdhary, A., Meis, J. F. G. M., & de Groot, T. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04618-22 · Cited by 23
DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs
Meagher, R. B., Lewis, Z., Ambati, S., & Lin, X. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114776 · Cited by 27
Yao, X., Mu, J., Zheng, Y., Wu, J., Zhu, W., & Wang, K. (2023) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2023.132481 · Cited by 23
Hernández-Pabón, J. C., Tabares, B., Gil, Ó., Lugo-Sánchez, C., Santana, A., Barón, A., & Firacative, C. (2024) · Journal of Fungi · doi:10.3390/jof10050326 · Cited by 30
“With an estimated 750,000 cases occurring yearly, this mycosis has mortality rates that often exceed 40%, despite patients receiving antifungal therapy [3,4].”
BackgroundEpithelial uptake leads to fungal killing in vivo and is aberrant in COPD-derived epithelial cells
Bertuzzi, M., Howell, G. J., Thomson, D. D., Fortune‐Grant, R., Möslinger, A., Dancer, P., van Rhijn, N., Motsi, N., Du, X., Codling, A., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109939 · Cited by 20
Derbie, A., Mekonnen, D. S., Woldeamanuel, Y., & Abebe, T. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05129-w · Cited by 27
“Despite the high burden of cryptococcal meningitis related morbidity and mortality in resource limited settings, reviewed data on prevalence of cryptococcal antigenemia and its predictors is missing [22, 23].”
BackgroundCryo-Electron Tomography of Candida glabrata Plasma Membrane Proteins
Jiménez‐Ortigosa, C., Jiang, J. B., Chen, M., Kuang, X., Healey, K. R., Castellano, P., Boparai, N., Ludtke, S. J., Perlin, D. S., & Dai, W. (2021) · Journal of Fungi · doi:10.3390/jof7020120 · Cited by 22
“Timely and appropriate antifungal treatment is crucial for the successful outcome of invasive fungal infections [1–4].”
BackgroundRajendrasozhan, S., Moll, H. E., Snoussi, M., et al. (2021) · Processes · doi:10.3390/pr9081351 · Cited by 22
Rahme, D., Ayoub, M., Shaito, K., Saleh, N., Assaf, S. A., & Lahoud, N. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07883-5 · Cited by 28
“In addition, an important reason behind the overall increased use of antifungals could be the increasing number of invasive fungal infections such as chronic pulmonary aspergillosis, cryptococcal meningitis in HIV/AIDs, invasive candidiasis, and Pneumocystis jirovecii pneumonia [28].”
BackgroundVanitha, P. R., Somashekaraiah, R., Divyashree, S., Pan, I., & Sreenivasa, M. Y. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1192449 · Cited by 22
Antifungal Activity of Mexican Propolis on Clinical Isolates of Candida Species
Rivera-Yañez, C. R., Ruiz-Hurtado, P. A., Reyes‐Reali, J., Mendoza‐Ramos, M. I., Vargas-Díaz, M. E., Hernández-Sánchez, K. M., Pozo‐Molina, G., Méndez-Catalá, C. F., García-Romo, G. S., Pedroza‐González, A., et al. (2022) · Molecules · doi:10.3390/molecules27175651 · Cited by 28
“Worldwide, the incidence of invasive Candida infections has been increasing at a rate of 700,000 cases per year, associated with considerable mortality [33,34].”
BackgroundZaccaron, A. Z., & Stergiopoulos, I. (2024) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2024.10.010 · Cited by 29
Warrilow, A. G. S., Parker, J. E., Price, C. L., Rolley, N. J., Nes, W. D., Kelly, D. E., & Kelly, S. L. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.07.011 · Cited by 26
Design, synthesis and antifungal activity of pterolactam-inspired amide Mannich bases
Dascălu, A., Ghinet, A., Lipka, E., Furman, C., Rigo, B., Fayeulle, A., & Billamboz, M. (2020) · Fitoterapia · doi:10.1016/j.fitote.2020.104581 · Cited by 21
Garvey, E. P., Sharp, J., Warn, P. A., Yates, C. M., Atari, M. I., Thomas, S., & Schotzinger, R. J. (2019) · Medical Mycology · doi:10.1093/mmy/myz092 · Cited by 26
Deaguero, I. G., Huda, M. N., Rodriguez, V., Zicari, J. E., Al-Hilal, T. A., Badruddoza, A. Z. M., & Nurunnabi, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060516 · Cited by 25
“Globally, 300 million people are inflicted with a serious fungal infection annually [1].”
BackgroundSoluble mediators in anti-fungal immunity
Dellière, S., Wong, S. S. W., & Aimanianda, V. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.05.005 · Cited by 26
Cheng, S. N., Tan, Z. G., Pandey, M., Srichana, T., Pichika, M. R., Gorain, B., & Choudhury, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121161 · Cited by 27
“Populations who are non-immunocompetent or with impaired lung function such as patients who suffer from HIV/AIDS, tuberculosis (TB), chronic obstructive pulmonary disease, asthma and cancers are at-high risk of fungal infection [14].”
BackgroundAnticapsular and Antifungal Activity of α-Cyperone
Horn, C., & Vediyappan, G. (2021) · Antibiotics · doi:10.3390/antibiotics10010051 · Cited by 25
“It is estimated that nearly a billion people are infected with mucosal or superficial fungal diseases and 150 million people are affected with invasive fungal diseases [1].”
BackgroundJiang, L., Huang, P., Ren, B., Song, Z., Zhu, G., He, W., Zhang, J., Oyeleye, A., Dai, H., Zhang, L., et al. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11226-w · Cited by 21
Aiming for a bull’s-eye: Targeting antifungals to fungi with dectin-decorated liposomes
Meagher, R. B., Lewis, Z., Ambati, S., & Lin, X. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009699 · Cited by 24
“Annual mortality rates for these diseases range from 10% to 90% [1,2], even though most”
BackgroundMuzaheed, M., Alshehri, B., Rabaan, A. A., El-Masry, O. S., Acharya, S., Alzahrani, F., Mutair, A. S. A., Alhumaid, S., Al‐Tawfiq, J. A., Muhammad, J., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.11.014 · Cited by 23
Pountain, A. W., Collette, J. R., Farrell, W. M., & Lorenz, M. C. (2021) · mBio · doi:10.1128/mbio.03317-21 · Cited by 21
Mucormycosis: The hidden and forgotten disease
Darwish, R. M., Almasri, M., & Almasri, M. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15487 · Cited by 25
“If the Indian data were to be included, the estimate of mucormycosis would be about 910,000 cases globally (Bongomin et al., 2017; Chakrabarti & Dhaliwal, 2013).”
BackgroundHost immune responses in the central nervous system during fungal infections
Reyes, E. Y., & Shinohara, M. L. (2022) · Immunological Reviews · doi:10.1111/imr.13101 · Cited by 23
“An early study using primary mouse astrocytes showed expression of Tlr2, 4, 5, and 9 and demonstrated that their gene expression levels could also be induced 172 .”
Babič, M. N., Gunde‐Cimerman, N., Breskvar, M., Džeroski, S., & Brandão, J. C. (2022) · Journal of Fungi · doi:10.3390/jof8080860 · Cited by 28
“Contrary to viral or bacterial infections, the symptoms of fungal infections usually appear later and are therefore more difficult to relate to the primary environmental source [34,43].”
BackgroundTropical Medicinal Plant Extracts from Indonesia as Antifungal Agents against Candida Albicans
Geraldi, A., Wardana, A. P., Aminah, N. S., Kristanti, A. N., Sadila, A. Y., Wijaya, N. H., Wijaya, M. R. A., Diningrum, N. I. D., Hajar, V. R., & Manuhara, Y. S. W. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2709274 · Cited by 33
“Furthermore, the estimated annual invasive candidiasis are 750,000 cases with a mortality rate of 40%–55%, especially in patients with risk factors such as immunodeficiency, advanced age, exposure to broad-spectrum antibiotics, cancer chemotherapy, organ transplantation, and prolonged stay in an intensive care setting…”
BackgroundMucormycosis in Africa: Epidemiology, diagnosis and treatment outcomes
Osaigbovo, I. I., Ekeng, B. E., Davies, A. A., & Oladele, R. O. (2023) · Mycoses · doi:10.1111/myc.13581 · Cited by 25
“Clinical type was based on the anatomic site affected and classified as (1) rhino- orbito- cerebral mucormycosis (ROCM), (2) pulmonary, (3) cutaneous, (4) gastrointestinal, (5) disseminated, and (6) other isolated organs.”
MethodSelf-citationPéret, V. A. C., Reis, R. C. F. M., Braga, S. F. P., Benedetti, M. D., Caldas, I. S., Carvalho, D. T., Santana, L. F. D. A., Johann, S., & de Souza, T. B. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115436 · Cited by 25
Small molecules restore azole activity against drug-tolerant and drug-resistant Candida isolates
Alabi, P., Gautier, C., Murphy, T. P., Gu, X., Lepas, M., Aimanianda, V., Sello, J. K., & Ene, I. V. (2023) · mBio · doi:10.1128/mbio.00479-23 · Cited by 30
Point-of-care testing for viral-associated pulmonary aspergillosis
Aerts, R., Autier, B., Gornicec, M., Prattes, J., Lagrou, K., Gangneux, J., & Hoenigl, M. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2257597 · Cited by 22
Dectin‐3‐targeted antifungal liposomes efficiently bind and kill diverse fungal pathogens
Choudhury, Q. J., Ambati, S., Link, C. D., Lin, X., Lewis, Z., & Meagher, R. B. (2023) · Molecular Microbiology · doi:10.1111/mmi.15174 · Cited by 21
Karkowska‐Kuleta, J., Kulig, K., Braś, G., Stelmaszczyk, K., Surowiec, M., Kozik, A., Karnas, E., Woźnicka, O., Zuba‐Surma, E. K., Pyza, E., et al. (2023) · Journal of Fungi · doi:10.3390/jof9111078 · Cited by 24
AFRbase: a database of protein mutations responsible for antifungal resistance
Jain, A., Singhal, N., & Kumar, M. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad677 · Cited by 22
Elgammal, Y., Salama, E. A., & Seleem, M. N. (2024) · Scientific Reports · doi:10.1038/s41598-024-52012-8 · Cited by 23
“2,6 .”
Khan, S. S., Hay, R. J., & Saunte, D. M. L. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20146 · Cited by 21
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.